← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	1,781	+44	+3%	$144B
2	2 Amgen AMGN $238B	1,182	+27	+2%	$76B
3	3 Eli Lilly LLY $1.13T	1,026	+21	+2%	$49.3B
4	4 Becton Dickinson BDX $52.4B	845	+14	+2%	$19.1B
5	5 McKesson MCK $116B	801	+9	+1%	$35B
6	6 Teva Pharmaceutical Industries Limited TEVA $48.1B	772	+44	+6%	$25B
7	7 Conagra Brands CAG $6.84B	614	-6	-1%	$8.68B
8	8 DaVita DVA $11.9B	473	+17	+4%	$12.2B
9	9 Novo Nordisk NVO $174B	461	+29	+7%	$8.34B
10	10 Regeneron Pharmaceuticals REGN $82.8B	453	+15	+3%	$22.1B
11	11 AstraZeneca AZN $261B	388	+8	+2%	$7.81B
12	12 ResMed RMD $33.8B	319	-10	-3%	$3.59B
13	13 Herbalife HLF $1.52B	308	-20	-6%	$6.68B
14	14 Accendra Health ACH $24M	245	+2	+0.8%	$2.17B
15	15 West Pharmaceutical WST $26.9B	226	-4	-2%	$2.81B
16	16 Opko Health OPK $1.19B	168	+12	+8%	$678M
17	17 Dr. Reddy's Laboratories RDY $10.8B	165	+16	+11%	$1.09B
18	18 MannKind Corp MNKD $990M	159	+15	+10%	$335M
19	19 Tootsie Roll Industries TR $2.93B	140	+2	+1%	$414M
20	20 DELISTED WW International WW	137	-42	-23%	$1.19B
21	21 Medifast MED $137M	132	+5	+4%	$373M
22	ARNA 22 DELISTED Arena Pharmaceuticals Inc ARNA	131	-3	-2%	$646M
23	23 Fresenius Medical Care FMS $11.8B	127	-8	-6%	$510M
24	24 Lexicon Pharmaceuticals LXRX $725M	103	-6	-6%	$813M
25	25 Alaunos Therapeutics TCRT $5.39M	96	+18	+23%	$255M